Cofactor Genomics

Cofactor Genomics announced the start of its first multicenter clinical trial.

Cofactor Genomics, Inc. is a commercial-stage company that decodes RNA. It named Chris Parker CEO.

“the [ImmunoPrism] assay has been able to define gene expression signals and identify immune cell signatures that differentiate patients who remain disease-free after three years from those who recurred within one year.”

“As cells continually transcribe and translate genetic information, the RNA intermediary may be a means of providing profound new insights into the health of any given tissue.”

The company says RNA changes dynamically and may provide a more accurate, earlier way to diagnose disease.

The passage says RNA leaves traces associated with flu, Parkinsons and cancer, describing RNA's roles in inflammation, neurons and copying malfunctioning DNA.

Jarret Glasscock is identified as CEO of Cofactor Genomics, and the text refers to an oncology drug entering clinical trials.

The page discusses RNA-seq as a research tool and describes a conversation about protein mass spectrometry.

The page says RNA-seq offers high technical reproducibility, dynamic range and discovery of novel transcripts compared with microarrays, while raising questions in transcriptome research.

Dr. Howard Bailey, former director of the UW Carbone Cancer Center, joins Cofactor Genomics as chief medical officer. He will guide the company's clinical strategy as it expands patient access to predictive RNA diagnostics.

Jul 2026 · Business WireNews article

Cofactor Genomics says Labcorp and Ascension Ventures have made strategic investments to support expansion of its OncoPrism immunotherapy-response diagnostics. The company says the investments will accelerate nationwide expansion and broaden patient access across U.S. cancer care networks.

Dec 2025 · Business WireNews article

Cofactor Genomics names Chris Parker CEO and board member as founder Jarret Glasscock transitions to president, CTO and board member. Glasscock is set to lead commercial growth of OncoPrism, the company’s Medicare-approved immunotherapy test, as Cofactor prepares for accelerated commercial growth and increased patient access.

Jan 2025 · Business WireNews article

Dr. Howard McLeod joins Cofactor Genomics’ advisory board to help integrate precision medicine into partnered hospitals. Cofactor is bringing its Medicare-approved OncoPrism test to health systems.

Oct 2024 · Business WireNews article